OBSERVATIONAL STUDY OF TREATMENT OF EPIDERMAL GROWTH FACTOR RECEPTOR ACTIVATING MUTATION POSITIVE (EGFRM plus ) ADVANCED OR RECURRENT NON-SMALL-CELL LUNG CANCER (NSCLC), AFTER RADIOLOGICAL PROGRESSION TO THE FIRST-LINE THERAPY WITH EGFR TYROSINE KINASE INHIBITORS (EGFR-TKI)

被引：0
|
作者：
Kunitoh, Hideo [1 ]
Tanai, Chiharu [2 ]
Hosomi, Yukio [3 ]
Yoh, Kiyotaka [4 ]
Goto, Yasushi [5 ]
Ohashi, Yasuo [6 ]
机构：
[1] Mitsui Mem Hosp, Tokyo, Japan
[2] Ntt Med Ctr, Div Respirol, Tokyo, Japan
[3] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Thorac Oncol & Resp Med, Tokyo, Japan
[4] Natl Canc Ctr Hosp East, Div Thorac Oncol, Kashiwa, Chiba, Japan
[5] Tokyo Univ Hosp, Dept Resp Med, Tokyo, Japan
[6] Univ Tokyo, Dept Biostat, Tokyo 1138654, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
EGFR; progression; RECIST; beyond PD;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.11-011
引用
收藏
页码：S597 / S598
页数：2
相关论文
共 50 条
  • [1] Observational study of treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) in activating EGFR-mutation-positive (EGFRm plus ) advanced or recurrent non-small cell lung cancer (NSCLC) after radiologic progression to first-line therapy with EGFR-TKI
    Hosomi, Yukio
    Tanai, Chiharu
    Yoh, Kiyotaka
    Goto, Yasushi
    Ohashi, Yasuo
    Kunitoh, Hideo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [2] Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study
    Goto, Yasushi
    Tanai, Chiharu
    Yoh, Kiyotaka
    Hosomi, Yukio
    Sakai, Hiroshi
    Kato, Terufumi
    Kaburagi, Takayuki
    Nishio, Makoto
    Kim, Young Hak
    Inoue, Akira
    Hasegawa, Yoshinori
    Isobe, Hiroshi
    Tomizawa, Yoshio
    Mori, Yoshiaki
    Minato, Koichi
    Yamada, Kazuhiko
    Ohashi, Yasuo
    Kunitoh, Hideo
    ESMO OPEN, 2017, 2 (04)
  • [3] Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors as a first-line treatment for postoperative recurrent and EGFR-mutated non-small-cell lung cancer
    Moriya, Tetsuji
    Hamaji, Masatsugu
    Yoshizawa, Akihiko
    Miyata, Ryo
    Noguchi, Misa
    Tamari, Shigeyuki
    Chiba, Naohisa
    Miyamoto, Hideaki
    Toyazaki, Toshiya
    Tanaka, Satona
    Yamada, Yoshito
    Yutaka, Yojiro
    Nakajima, Daisuke
    Ohsumi, Akihiro
    Menju, Toshi
    Date, Hiroshi
    INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY, 2022, 34 (03) : 416 - 423
  • [4] Impact of Weight Loss at Presentation on Survival in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) Sensitive Mutant Advanced Non-small Cell Lung Cancer (NSCLC) Treated with First-line EGFR-TKI
    Lin, Liping
    Zhao, Juanjuan
    Hu, Jiazhu
    Huang, Fuxi
    Han, Jianjun
    He, Yan
    Cao, Xiaolong
    JOURNAL OF CANCER, 2018, 9 (03): : 528 - 534
  • [5] Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors
    Eric Nadler
    Melissa Pavilack
    Janet L. Espirito
    Jamyia Clark
    Ancilla Fernandes
    Advances in Therapy, 2020, 37 : 946 - 954
  • [6] Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors
    Nadler, Eric
    Pavilack, Melissa
    Espirito, Janet L.
    Clark, Jamyia
    Fernandes, Ancilla
    ADVANCES IN THERAPY, 2020, 37 (02) : 946 - 954
  • [7] EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer
    Nan, Xueli
    Xie, Chao
    Yu, Xueyan
    Liu, Jie
    ONCOTARGET, 2017, 8 (43) : 75712 - 75726
  • [8] Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors combined with chemotherapy in first-line treatment in an advanced non-small cell lung cancer patient with EGFR sensitive mutation
    Huang, Aimi
    Li, Rong
    Zhao, Jikai
    Wang, Xiaofei
    Jin, Bo
    Niu, Yanjie
    Zhang, Jie
    Jiang, Liyan
    Han, Baohui
    THORACIC CANCER, 2016, 7 (05) : 614 - 618
  • [9] The mutation status of the epidermal growth factor receptor (EGFR) as a selection criterion for therapy with EGFR tyrosine kinase inhibitors (TKI's) in non-small cell lung cancer (NSCLC).
    Mathy, A.
    Nederlof, P.
    Boerrigter, L.
    Van 't Veer, L.
    De Jong, D.
    Baas, P.
    Burgers, S.
    Van Zandwijk, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 558S - 558S
  • [10] Osimertinib vs standard of care (SoC) EGFR-TKI as first-line treatment in patients with EGFR-TKI sensitising mutation (EGFRm) positive advanced non-small cell lung cancer (NSCLC): FLAURA Asian subset
    Cho, B. C.
    Chewaskulyong, B.
    Lee, K. H.
    Dechaphunkul, A.
    Sriuranpong, V.
    Imamura, F.
    Ohe, Y.
    Nogami, N.
    Kurata, T.
    Okamoto, I.
    Zhou, C.
    Cheng, Y.
    Cho, E. K.
    Jye, V. P.
    Lee, J-S.
    Mann, H.
    Saggese, M.
    Reungwetwattana, T.
    ANNALS OF ONCOLOGY, 2017, 28 : 190 - 190
12345